Invex\u83b7\u5f97\u6cbb\u7597\u9885\u5185\u538b\u5347\u9ad8\u7684\u6b27\u6d32\u4e13\u5229\uff0c<\/a>\u5305\u62ec\u4f7f\u7528GLP-1\u53d7\u4f53\u6fc0\u52a8\u5242\uff0c\u5305\u62ecPresendin (Exenatide)\uff0c\u4ee5\u964d\u4f4eIIH\u76f8\u5173\u7684\u9885\u5185\u538b\u5347\u9ad8\u3002<\/p>\n\u8be5\u4e13\u5229\u7684\u77e5\u8bc6\u4ea7\u6743\u4fdd\u62a4\u5c06\u81f3\u5c11\u6301\u7eed\u52302035\u5e748\u6708\u3002<\/p>\n
\u5b83\u9075\u5faa\u4e86\u8be5\u516c\u53f8\u5728\u7f8e\u56fd\u548c\u65e5\u672c\u9881\u53d1\u7684\u4e13\u5229\uff0c\u4ece\u800c\u5728Invex\u63a8\u8fdb\u5176Presendin\u7684\u4e34\u5e8a\u5f00\u53d1\u8ba1\u5212\u65f6\u63d0\u4f9b\u5e7f\u6cdb\u7684\u77e5\u8bc6\u4ea7\u6743\u4fdd\u62a4\u3002<\/p>\n
Exenatide\u5728\u7f8e\u56fd\u548c\u6b27\u6d32\u4e5f\u83b7\u5f97\u5b64\u513f\u836f\u6388\u6743\uff0c\u5206\u522b\u63d0\u4f9b7\u5e74\u548c10\u5e74\u7684\u5e02\u573a\u72ec\u5360\u6743\u3002<\/p>\n
\u5f3a\u52b2\u7684\u8d22\u52a1\u72b6\u51b5<\/h2>\n
Invex\u57289\u6708\u4efd\u5b63\u5ea6\u7ed3\u675f\u65f6\u8d22\u52a1\u72b6\u51b5\u826f\u597d\uff0c\u73b0\u91d1\u548c\u73b0\u91d1\u7b49\u4ef7\u7269\u4e3a3200\u4e07\u6fb3\u5143\u3002\u672c\u671f\u95f4\u73b0\u91d1\u6d41\u51fa\u603b\u989d\u4e3a740000\u6fb3\u5143\u3002<\/p>\n
\u73b0\u91d1\u6d41\u51fa\u5305\u62ec\u4e0e\u516c\u53f8\u8ba1\u5212\u7684\u7b2c\u4e09\u9636\u6bb5\u4e34\u5e8a\u8bd5\u9a8c\u76f8\u5173\u7684\u7814\u53d1\u652f\u51fa\u3001FDA\u53cd\u9988\u7684\u76d1\u7ba1\u548c\u4e13\u5bb6\u5efa\u8bae\u3001\u77e5\u8bc6\u4ea7\u6743\u548c\u7ba1\u7406\u6210\u672c\u3002<\/p>\n
Invex\u8868\u793a\uff0c\u968f\u7740\u516c\u53f8\u5f00\u59cb\u4ecePeptron\u8ba2\u8d2d\u7528\u4e8e\u4e34\u5e8a\u8bd5\u9a8c\u7684Presendin\uff0c\u9884\u8ba1\u672a\u6765\u51e0\u4e2a\u5b63\u5ea6\u73b0\u91d1\u6d41\u51fa\u5c06\u589e\u52a0\u3002<\/p>\n
\u7b2c\u4e09\u9636\u6bb5\u8bd5\u9a8c\u5c06\u4e8e2022\u5e74\u4e0a\u534a\u5e74\u5f00\u59cb\u3002<\/p>\n","protected":false},"excerpt":{"rendered":"
\u4e34\u5e8a\u9636\u6bb5\u751f\u7269\u5236\u836f\u516c\u53f8Invex Therapeutics (ASX: IXC)\u62a5\u544a\u79f0\uff0c\u5176\u6cbb\u7597\u9885\u5185\u538b\u5347\u9ad8\u76f8\u5173\u795e\u7ecf\u75be\u75c5\u7684\u836f\u7269Presendin\u7684\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u57289\u6708\u4efd\u5b63\u5ea6\u53d6\u5f97\u4e86\u5f3a\u52b2\u8fdb\u5c55\u3002 Presendin\u662fInvex\u4e3a\u73b0\u6709\u836f\u7269Exenatide\u547d\u540d\u7684\u5546\u6807\u540d\uff0c\u8be5\u836f\u7269\u5df2\u88ab\u6279\u51c6\u7528\u4e8e\u6cbb\u75972\u578b\u7cd6\u5c3f\u75c5\u3002Invex\u5c06\u5176\u91cd\u65b0\u7528\u4e8e\u9002\u5e94\u75c7\uff0c\u5305\u62ec\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b(IIH)\u3001\u6025\u6027\u4e2d\u98ce\u548c\u521b\u4f24\u6027\u8111\u635f\u4f24\u3002 \u4e0a\u4e2a\u6708\uff0c\u8be5\u516c\u53f8\u4e0e\u97e9\u56fd\u751f\u7269\u5236\u836f\u516c\u53f8Peptron\u7b7e\u8ba2\u4e86\u72ec\u5bb6\u5408\u4f5c\u534f\u8bae\uff0c\u5b9e\u73b0\u4e86\u751f\u4ea7\u7684\u91cc\u7a0b\u7891\u3002 \u8be5\u4ea4\u6613\u6d89\u53caPeptron\u5411Invex\u63d0\u4f9b\u5176\u77e5\u8bc6\u4ea7\u6743\uff0c\u5305\u62ec\u4e0e\u5176\u4e13\u5229\u7f13\u91ca\u5236\u5242Exenatide\u76f8\u5173\u7684\u5927\u91cf\u4e34\u5e8a\u524d\u548c\u4e34\u5e8a\u6570\u636e\u3002Exenatide\u5c06\u88ab\u6807\u8bb0\u4e3aPresendin\uff0c\u7528\u4e8eInvex\u5728IIH\u7684\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u5982\u679c\u76d1\u7ba1\u90e8\u95e8\u6279\u51c6\uff0c\u4e5f\u53ef\u7528\u4e8e\u5546\u4e1a\u7528\u9014\u3002 \u8be5\u72ec\u5bb6\u534f\u8bae\u9002\u7528\u4e8e\u5168\u7403\uff0c\u5e76\u4e3a\u4e34\u5e8a\u7814\u7a76\u548c\u9996\u6b21\u9500\u552e\u540e\u7684\u593410\u5e74\u63d0\u4f9b\u6bcf\u5242\u91cfPresendin\u7684\u786e\u5b9a\u4ef7\u683c\u3002 \u6b64\u5916\uff0cInvex\u8fd8\u5411Peptron\u6388\u4e88\u4e86IIH\u5728\u97e9\u56fd\u7684\u72ec\u5bb6\u8bb8\u53ef\u3002 \u4e34\u5e8a\u68c0\u67e5 \u672c\u5b63\u5ea6\uff0cInvex\u53ec\u96c6\u4e86\u4e3b\u8981\u610f\u89c1\u9886\u8896\u7684\u79d1\u5b66\u54a8\u8be2\u4f1a\u8bae\uff0c\u8be5\u7814\u7a76\u65e8\u5728\u68c0\u9a8c\u8bbe\u8ba1\u4e00\u9879\u9488\u5bf9Presendin\u6ce8\u518c\u7684\u5355\u4e00\u7f8e\u56fd\/\u6b27\u76df\u4e34\u5e8a\u8bd5\u9a8c\u7684\u53ef\u884c\u6027\uff0c\u8be5\u4e34\u5e8a\u8bd5\u9a8c\u5c06\u6ee1\u8db3\u7f8e\u56fd\u98df\u54c1\u548c\u836f\u7269\u7ba1\u7406\u5c40(FDA)\u548c\u6b27\u6d32\u836f\u54c1\u7ba1\u7406\u5c40(EMA)\u7684\u5e02\u573a\u6279\u51c6\u8981\u6c42\u3002 \u8be5\u7efc\u8ff0\u5305\u62ec\u4e00\u9879\u72ec\u7acb\u3001\u5168\u9762\u7684IIH\u60a3\u8005\u6570\u636e\u7684\u4e34\u5e8a\u7efc\u8ff0\uff0c\u56e0\u4e3a\u5b83\u4e0e\u5468\u754c\u5e73\u5747\u504f\u5dee(PMD)\u6709\u5173\uff0c\u5e76\u7efc\u8ff0\u4e86\u79d1\u5b66\u6587\u732e\u4e2d\u5df2\u53d1\u8868\u7684\u4e34\u5e8a\u8bc1\u636e\u3002 Invex\u8463\u4e8b\u4f1a\u7684\u5ba1\u67e5\u548c\u6218\u7565\u51b3\u7b56\u7ed3\u679c\uff0c\u5305\u62ec\u9996\u9009\u7684\u4e34\u5e8a\u548c\u76d1\u7ba1\u8ba1\u5212\uff0c\u9884\u8ba1\u5c06\u5728\u4eca\u5e74\u7b2c\u56db\u5b63\u5ea6\u65e9\u4e9b\u65f6\u5019\u516c\u5e03\u3002 \u6b27\u6d32\u4e13\u5229\u4fdd\u62a4 \u4eca\u5e748\u6708\uff0cInvex\u83b7\u5f97\u6cbb\u7597\u9885\u5185\u538b\u5347\u9ad8\u7684\u6b27\u6d32\u4e13\u5229\uff0c\u5305\u62ec\u4f7f\u7528GLP-1\u53d7\u4f53\u6fc0\u52a8\u5242\uff0c\u5305\u62ecPresendin (Exenatide)\uff0c\u4ee5\u964d\u4f4eIIH\u76f8\u5173\u7684\u9885\u5185\u538b\u5347\u9ad8\u3002 \u8be5\u4e13\u5229\u7684\u77e5\u8bc6\u4ea7\u6743\u4fdd\u62a4\u5c06\u81f3\u5c11\u6301\u7eed\u52302035\u5e748\u6708\u3002 \u5b83\u9075\u5faa\u4e86\u8be5\u516c\u53f8\u5728\u7f8e\u56fd\u548c\u65e5\u672c\u9881\u53d1\u7684\u4e13\u5229\uff0c\u4ece\u800c\u5728Invex\u63a8\u8fdb\u5176Presendin\u7684\u4e34\u5e8a\u5f00\u53d1\u8ba1\u5212\u65f6\u63d0\u4f9b\u5e7f\u6cdb\u7684\u77e5\u8bc6\u4ea7\u6743\u4fdd\u62a4\u3002 Exenatide\u5728\u7f8e\u56fd\u548c\u6b27\u6d32\u4e5f\u83b7\u5f97\u5b64\u513f\u836f\u6388\u6743\uff0c\u5206\u522b\u63d0\u4f9b7\u5e74\u548c10\u5e74\u7684\u5e02\u573a\u72ec\u5360\u6743\u3002 \u5f3a\u52b2\u7684\u8d22\u52a1\u72b6\u51b5 Invex\u57289\u6708\u4efd\u5b63\u5ea6\u7ed3\u675f\u65f6\u8d22\u52a1\u72b6\u51b5\u826f\u597d\uff0c\u73b0\u91d1\u548c\u73b0\u91d1\u7b49\u4ef7\u7269\u4e3a3200\u4e07\u6fb3\u5143\u3002\u672c\u671f\u95f4\u73b0\u91d1\u6d41\u51fa\u603b\u989d\u4e3a740000\u6fb3\u5143\u3002 \u73b0\u91d1\u6d41\u51fa\u5305\u62ec\u4e0e\u516c\u53f8\u8ba1\u5212\u7684\u7b2c\u4e09\u9636\u6bb5\u4e34\u5e8a\u8bd5\u9a8c\u76f8\u5173\u7684\u7814\u53d1\u652f\u51fa\u3001FDA\u53cd\u9988\u7684\u76d1\u7ba1\u548c\u4e13\u5bb6\u5efa\u8bae\u3001\u77e5\u8bc6\u4ea7\u6743\u548c\u7ba1\u7406\u6210\u672c\u3002 Invex\u8868\u793a\uff0c\u968f\u7740\u516c\u53f8\u5f00\u59cb\u4ecePeptron\u8ba2\u8d2d\u7528\u4e8e\u4e34\u5e8a\u8bd5\u9a8c\u7684Presendin\uff0c\u9884\u8ba1\u672a\u6765\u51e0\u4e2a\u5b63\u5ea6\u73b0\u91d1\u6d41\u51fa\u5c06\u589e\u52a0\u3002 \u7b2c\u4e09\u9636\u6bb5\u8bd5\u9a8c\u5c06\u4e8e2022\u5e74\u4e0a\u534a\u5e74\u5f00\u59cb\u3002<\/p>\n","protected":false},"author":5,"featured_media":13545,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[3],"tags":[273],"yoast_head":"\n
Invex Therapeutics\u62a5\u544aPresendin\u5f00\u53d1\u7e41\u5fd9\u5b63\u5ea6<\/title>\n<meta name=\"description\" content=\"\u4e34\u5e8a\u9636\u6bb5\u751f\u7269\u5236\u836f\u516c\u53f8Invex Therapeutics (ASX: IXC)\u62a5\u544a\u79f0\uff0c\u5176\u6cbb\u7597\u9885\u5185\u538b\u5347\u9ad8\u76f8\u5173\u795e\u7ecf\u75be\u75c5\u7684\u836f\u7269Presendin\u7684\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u57289\u6708\u4efd\u5b63\u5ea6\u53d6\u5f97\u4e86\u5f3a\u52b2\u8fdb\u5c55\u3002\" \/>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Invex Therapeutics\u62a5\u544aPresendin\u5f00\u53d1\u7e41\u5fd9\u5b63\u5ea6\" \/>\n<meta property=\"og:description\" content=\"\u4e34\u5e8a\u9636\u6bb5\u751f\u7269\u5236\u836f\u516c\u53f8Invex Therapeutics (ASX: IXC)\u62a5\u544a\u79f0\uff0c\u5176\u6cbb\u7597\u9885\u5185\u538b\u5347\u9ad8\u76f8\u5173\u795e\u7ecf\u75be\u75c5\u7684\u836f\u7269Presendin\u7684\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u57289\u6708\u4efd\u5b63\u5ea6\u53d6\u5f97\u4e86\u5f3a\u52b2\u8fdb\u5c55\u3002\" \/>\n<meta property=\"og:url\" content=\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-reports-busy-quarter-presendin-development\/\" \/>\n<meta property=\"og:site_name\" content=\"smallcapsCN\" \/>\n<meta property=\"article:published_time\" content=\"2021-10-20T01:07:52+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-08-29T18:01:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/smallcapscn.x5view.co\/wp-content\/uploads\/2023\/08\/Invex-Therapeutics-ASX-IXC-Presendin-development-neurological-conditions-intracranial-pressure-Exenatide-brain.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"640\" \/>\n\t<meta property=\"og:image:height\" content=\"400\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Small Caps\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Small Caps\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-reports-busy-quarter-presendin-development\/\",\"url\":\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-reports-busy-quarter-presendin-development\/\",\"name\":\"Invex Therapeutics\u62a5\u544aPresendin\u5f00\u53d1\u7e41\u5fd9\u5b63\u5ea6\",\"isPartOf\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/#website\"},\"datePublished\":\"2021-10-20T01:07:52+00:00\",\"dateModified\":\"2023-08-29T18:01:43+00:00\",\"author\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/ba96c5f4870849ab11e50adb62f2df74\"},\"description\":\"\u4e34\u5e8a\u9636\u6bb5\u751f\u7269\u5236\u836f\u516c\u53f8Invex Therapeutics (ASX: IXC)\u62a5\u544a\u79f0\uff0c\u5176\u6cbb\u7597\u9885\u5185\u538b\u5347\u9ad8\u76f8\u5173\u795e\u7ecf\u75be\u75c5\u7684\u836f\u7269Presendin\u7684\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u57289\u6708\u4efd\u5b63\u5ea6\u53d6\u5f97\u4e86\u5f3a\u52b2\u8fdb\u5c55\u3002\",\"breadcrumb\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-reports-busy-quarter-presendin-development\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-reports-busy-quarter-presendin-development\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-reports-busy-quarter-presendin-development\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/smallcapscn.x5view.co\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Invex Therapeutics\u62a5\u544aPresendin\u5f00\u53d1\u7e41\u5fd9\u5b63\u5ea6\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#website\",\"url\":\"https:\/\/smallcapscn.x5view.co\/\",\"name\":\"smallcapsCN\",\"description\":\"Just another WordPress site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/smallcapscn.x5view.co\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/ba96c5f4870849ab11e50adb62f2df74\",\"name\":\"Small Caps\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/5631bbe5d71ed71e3a6c301df6f973d0?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/5631bbe5d71ed71e3a6c301df6f973d0?s=96&d=mm&r=g\",\"caption\":\"Small Caps\"},\"description\":\"Small Caps provides coverage on Australian ASX listed small cap stocks across all sectors: mining, resources, energy, biotech, technology, juniors and IPOs.\",\"url\":\"https:\/\/smallcapscn.x5view.co\/?author=5\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Invex Therapeutics\u62a5\u544aPresendin\u5f00\u53d1\u7e41\u5fd9\u5b63\u5ea6","description":"\u4e34\u5e8a\u9636\u6bb5\u751f\u7269\u5236\u836f\u516c\u53f8Invex Therapeutics (ASX: IXC)\u62a5\u544a\u79f0\uff0c\u5176\u6cbb\u7597\u9885\u5185\u538b\u5347\u9ad8\u76f8\u5173\u795e\u7ecf\u75be\u75c5\u7684\u836f\u7269Presendin\u7684\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u57289\u6708\u4efd\u5b63\u5ea6\u53d6\u5f97\u4e86\u5f3a\u52b2\u8fdb\u5c55\u3002","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Invex Therapeutics\u62a5\u544aPresendin\u5f00\u53d1\u7e41\u5fd9\u5b63\u5ea6","og_description":"\u4e34\u5e8a\u9636\u6bb5\u751f\u7269\u5236\u836f\u516c\u53f8Invex Therapeutics (ASX: IXC)\u62a5\u544a\u79f0\uff0c\u5176\u6cbb\u7597\u9885\u5185\u538b\u5347\u9ad8\u76f8\u5173\u795e\u7ecf\u75be\u75c5\u7684\u836f\u7269Presendin\u7684\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u57289\u6708\u4efd\u5b63\u5ea6\u53d6\u5f97\u4e86\u5f3a\u52b2\u8fdb\u5c55\u3002","og_url":"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-reports-busy-quarter-presendin-development\/","og_site_name":"smallcapsCN","article_published_time":"2021-10-20T01:07:52+00:00","article_modified_time":"2023-08-29T18:01:43+00:00","og_image":[{"width":640,"height":400,"url":"https:\/\/smallcapscn.x5view.co\/wp-content\/uploads\/2023\/08\/Invex-Therapeutics-ASX-IXC-Presendin-development-neurological-conditions-intracranial-pressure-Exenatide-brain.jpg","type":"image\/jpeg"}],"author":"Small Caps","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Small Caps"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-reports-busy-quarter-presendin-development\/","url":"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-reports-busy-quarter-presendin-development\/","name":"Invex Therapeutics\u62a5\u544aPresendin\u5f00\u53d1\u7e41\u5fd9\u5b63\u5ea6","isPartOf":{"@id":"https:\/\/smallcapscn.x5view.co\/#website"},"datePublished":"2021-10-20T01:07:52+00:00","dateModified":"2023-08-29T18:01:43+00:00","author":{"@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/ba96c5f4870849ab11e50adb62f2df74"},"description":"\u4e34\u5e8a\u9636\u6bb5\u751f\u7269\u5236\u836f\u516c\u53f8Invex Therapeutics (ASX: IXC)\u62a5\u544a\u79f0\uff0c\u5176\u6cbb\u7597\u9885\u5185\u538b\u5347\u9ad8\u76f8\u5173\u795e\u7ecf\u75be\u75c5\u7684\u836f\u7269Presendin\u7684\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u57289\u6708\u4efd\u5b63\u5ea6\u53d6\u5f97\u4e86\u5f3a\u52b2\u8fdb\u5c55\u3002","breadcrumb":{"@id":"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-reports-busy-quarter-presendin-development\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/smallcapscn.x5view.co\/invex-therapeutics-reports-busy-quarter-presendin-development\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-reports-busy-quarter-presendin-development\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/smallcapscn.x5view.co\/"},{"@type":"ListItem","position":2,"name":"Invex Therapeutics\u62a5\u544aPresendin\u5f00\u53d1\u7e41\u5fd9\u5b63\u5ea6"}]},{"@type":"WebSite","@id":"https:\/\/smallcapscn.x5view.co\/#website","url":"https:\/\/smallcapscn.x5view.co\/","name":"smallcapsCN","description":"Just another WordPress site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/smallcapscn.x5view.co\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/ba96c5f4870849ab11e50adb62f2df74","name":"Small Caps","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/5631bbe5d71ed71e3a6c301df6f973d0?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/5631bbe5d71ed71e3a6c301df6f973d0?s=96&d=mm&r=g","caption":"Small Caps"},"description":"Small Caps provides coverage on Australian ASX listed small cap stocks across all sectors: mining, resources, energy, biotech, technology, juniors and IPOs.","url":"https:\/\/smallcapscn.x5view.co\/?author=5"}]}},"_links":{"self":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/4026"}],"collection":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4026"}],"version-history":[{"count":1,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/4026\/revisions"}],"predecessor-version":[{"id":13544,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/4026\/revisions\/13544"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/media\/13545"}],"wp:attachment":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4026"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4026"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4026"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}